The Science Behind Why Ketamine Works When Antidepressants Don't
A recent review published in Psychiatric Times takes a deep look at how glutamate-targeting therapies are changing the treatment landscape for people with treatment-resistant depression (TRD). The piece centers on two FDA-approved glutamatergic agents — esketamine (Spravato) and dextromethorphan-bupropion (Auvelity) — and makes a compelling case for why targeting the glutamate system offers something fundamentally different from traditional antidepressants that work on serotonin, dopamine, or norepinephrine.
For the millions of people who have cycled through two or more antidepressant trials without adequate relief, this distinction matters enormously. The review explains that glutamate-based treatments work by promoting synaptogenesis — the formation of new synaptic connections in the brain — rather than simply adjusting neurotransmitter levels. This mechanism produces faster relief, often within hours to days rather than the four to six weeks typically required for SSRIs or SNRIs to take effect.
While the review focuses primarily on esketamine nasal spray and dextromethorphan-bupropion, the underlying neuroscience applies directly to the entire ketamine therapeutic class — including the sublingual troches that many patients are now using as part of structured at-home protocols.
Where Ketamine Troches Fit Into the Glutamatergic Picture
Esketamine nasal spray and racemic ketamine (the form used in IV infusions and compounded troches) both act on NMDA glutamate receptors, but the delivery methods, bioavailability profiles, and practical treatment workflows are quite different. Understanding these distinctions helps patients and prescribers make more informed decisions.
IV ketamine infusions deliver the drug directly into the bloodstream, producing peak plasma concentrations quickly and predictably. This makes them effective for acute interventions but requires clinic visits, IV access, and monitoring — barriers that limit access for many patients.
Esketamine nasal spray is FDA-approved for TRD and major depressive disorder with suicidal ideation, but it must be administered in a certified healthcare setting under observation. Patients cannot take it home.
Ketamine troches — compounded sublingual or buccal lozenges — occupy a distinct and increasingly important niche. They dissolve under the tongue or against the cheek, allowing ketamine to absorb through the oral mucosa before the remainder passes through the GI tract. Bioavailability is lower than IV (roughly 25–35% compared to nearly 100% with infusion), but the troche format enables something the other options cannot: a structured, supervised at-home dosing protocol.
For patients who have already been stabilized through infusions or who are appropriate candidates for outpatient-only treatment, troches allow consistent access to glutamatergic therapy without the logistical and financial burden of repeated clinic visits. This is particularly meaningful for those in rural areas, those with mobility limitations, or those managing demanding work and family schedules.
Key Takeaway
Glutamate-targeting treatments like ketamine work differently than standard antidepressants — they rebuild synaptic connections rather than adjusting neurotransmitter levels. Ketamine troches tap into this same mechanism at home, but their lower bioavailability means dosing precision and protocol design matter more, not less. Always work with a prescriber experienced in glutamatergic therapy to dial in your troche dose appropriately.
What This Means for Troche Access, Compounding, and Safety
The growing clinical and research focus on glutamatergic treatments for TRD is good news for troche patients in a few concrete ways.
Legitimacy and prescriber awareness: As glutamate-based approaches become more mainstream in psychiatry, more clinicians are gaining familiarity with the mechanism and the evidence base. This makes it easier to have informed conversations about compounded ketamine troches as part of a broader TRD management plan — rather than treating them as an outlier or fringe option.
Compounding considerations: Troches are not FDA-approved finished drug products — they are compounded by licensed pharmacies to a prescriber's specifications. Strength, base formulation, and absorption enhancers can vary between compounding pharmacies. The review's emphasis on dose-dependent synaptogenesis underscores why getting the compounding right matters: too low a dose may be subtherapeutic; too high without proper titration increases the risk of dissociative side effects or misuse.
Dosing routines and maintenance: The research literature increasingly supports the idea that ketamine's antidepressant effects are not permanent after a single course. Maintenance dosing — whether via periodic infusions, nasal spray sessions, or scheduled troche use — is an active area of clinical discussion. For troche patients, this often translates to an induction phase (more frequent dosing) followed by a maintenance schedule tailored to individual response. Your prescriber should be revisiting this schedule regularly based on how you're doing.
Comparison with other glutamatergic options: Dextromethorphan-bupropion (Auvelity) is an oral pill taken daily at home — a format that's familiar and convenient. However, it works through a different mechanism than ketamine and has a distinct side effect and interaction profile. It is not a substitute for ketamine troches, and vice versa. Patients exploring TRD treatment options should discuss with their provider which agent — or combination approach — fits their clinical picture.
The Bottom Line for Troche Patients
Research like this review in Psychiatric Times reinforces that the shift toward glutamate-based depression treatment is not a trend — it reflects a deeper understanding of what goes wrong in the brains of people with TRD and how to address it. Ketamine troches sit squarely within that therapeutic framework. Their value lies in making consistent, accessible glutamatergic treatment possible outside the clinic, but that convenience comes with real responsibilities: working with a knowledgeable prescriber, sourcing from a reputable compounding pharmacy, following a structured protocol, and monitoring your response over time.
Read the full review at Psychiatric Times.
Share